Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Exchanges $2.1 Million of Debt for Equity, Streamlining Capital Structure and Simplifying Balance Sheet
CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future NEW YORK , April 22, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that it has entered into an Exchange Agreement relating to a $2.1 million
View HTML
Toggle Summary Predictive Oncology (NASDAQ: POAI) CEO Discusses ‘Major Asset’ in Exclusive Interview
NEW YORK , April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz , in an interview with NetworkNewsWire (NNW), discussed the Predictive Oncology’s distinctive business model and significant
View HTML
Toggle Summary Predictive Oncology Reports 2019 Full-year Financial Results
MINNEAPOLIS , April 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for its full
View HTML
Toggle Summary POAI Subsidiary Helomics Continues Progress Towards Goal of Developing an AI-Driven Predictive Model of Ovarian Cancer
MINNEAPOLIS , March 31, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics
View HTML
Toggle Summary Predictive Oncology Inc. Announces Completion of $3.5 Million Private Placement
MINNEAPOLIS , March 23, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Inc. Announces $3.5 Million Private Placement
MINNEAPOLIS , March 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS)
With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development MINNEAPOLIS , March 12, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial
View HTML
Toggle Summary Predictive Oncology Provides Acquisition Update, Stresses Importance of AI in New Anti-Cancers, Anti-Virals and Vaccines
POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines MINNEAPOLIS , March 02, 2020 (GLOBE NEWSWIRE) -- Amid mounting concern over
View HTML
Toggle Summary Predictive Oncology Inc. Appoints Dan Handley, M.S., Ph.D. to Board of Directors
MINNEAPOLIS , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Launches Innovative Specialty Media for Growing Ovarian Tumors in the Lab
New Formulations Will Speed Discovery of Biomarkers and Precision Therapies MINNEAPOLIS , Feb. 05, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor
View HTML